Prévisions

Aucune donnée d'analyste n'est disponible pour cette entreprise.

Actualités Accéder au fil d'actualités

Eco Animal Health extends credit line with NatWest until mid-2031

Eco Animal Health has renewed its revolving credit facility with NatWest until 30 June 2031 and maintained availability of up to £10 million. In addition, the £5 million overdraft facility was renewed, bringing total bank facilities to £15 million. The agreement was concluded on more favourable terms; the facility is currently undrawn and is intended to provide liquidity for expansion initiatives. The company is preparing audited annual results for the year ended 31 March 2026 and expects to publish them in mid‑July 2026. » Plus sur de.investing.com
Eco Animal Health obtains US safety clearance for poultry vaccine ECOVAXXIN® MG

The Eco Animal Health Group has received a positive safety assessment from the USDA for the live vaccine ECOVAXXIN® MG against Mycoplasma gallisepticum. The assessment confirms safety for chickens as well as avian non-target species such as turkeys and quail, and shows no reversion or increase in virulence after passage through chickens. Eco Animal Health plans to file the final approval submission in the U.S. by the end of 2027 and also expects the market launch of another vaccine, ECOVAXXIN® MS, at the end of 2026. » Plus sur de.investing.com
ECO Animal Health plans EU-wide launch of poultry vaccine ECOVAXXIN MS

ECO Animal Health will roll out ECOVAXXIN MS across the EU in 2026 and 2027; approval by the European Commission was granted in December 2025. The vaccine protects laying and breeding hens from four weeks of age against Mycoplasma synoviae and is intended to cover markets in the seven largest egg‑producing countries with more than 220 million birds. ECO has signed distribution agreements, will use its existing network and plans an official launch on 30 June–1 July 2026 in Madrid. The company expects an immediate improvement in margins and a material contribution to EBITDA in fiscal year 2027/2028. » Plus sur de.investing.com

Dividendes historiques Dividendes

Tous les indicateurs de dividendes Tous les indicateurs

En 2021, Eco Animal Health a déjà versé 0,0118 € de dividendes. Le dernier versement a eu lieu en octobre 2021.

Données financières de l'entreprise

Au dernier trimestre, Eco Animal Health a réalisé un chiffre d'affaires de 55,06 M € et un bénéfice net de 2,92 M €

(EUR)	mars 2026	YoY
Chiffre d'affaires	55,06 M	-
Bénéfice brut	26,25 M	-
Bénéfice net	2,92 M	-
EBITDA	6,66 M	-

Données fondamentales

Indicateur	Valeur
Capitalisation boursière	76,17 M €
Nombre d'actions	66,71 M
Plus haut/bas sur 52 semaines	1,36 € - 0,84 €
Dividendes	Non
Bêta	0,70
Ratio P/E	30,34
Ratio PEG	1,04
Ratio P/B	0,76
Ratio P/S	0,75

Profil de l'entreprise

Die ECO Animal Health Group plc entwickelt, registriert und vermarktet zusammen mit ihren Tochtergesellschaften weltweit pharmazeutische Produkte für Tiere. Das Unternehmen bietet Aivlosin an, ein Makrolid-Antibiotikum für die Behandlung von Darm- und Atemwegserkrankungen bei Schweinen und Geflügel. Außerdem bietet es Generika wie Ecomectin, Ecoheart, Ecotraz und Ecomintic an, bei denen es sich um Endectozide und andere Antiparasitika zur Behandlung und Vorbeugung von Parasiten wie Würmern, Zecken und Läusen bei Rindern, Schafen, Schweinen, Pferden und Hunden handelt, sowie Chlortetracyclin und Oxytetracyclin zur Behandlung von bakteriellen Infektionen bei Schweinen, Geflügel und Rindern. Die ECO Animal Health Group plc wurde 1972 gegründet und hat ihren Hauptsitz in New Malden, Vereinigtes Königreich.